Contact
Please use this form to send email to PR contact of this press release:
Ultragenyx Receives Breakthrough Therapy Designation for KRN23 in Pediatric Patients with X-Linked Hypophosphatemia
TO:
Please use this form to send email to PR contact of this press release:
Ultragenyx Receives Breakthrough Therapy Designation for KRN23 in Pediatric Patients with X-Linked Hypophosphatemia
TO: